ATTO Technology Announces FibreBridge™ embedded in latest release of NetApp MetroCluster solution
Third generation of data protection solution continues longstanding collaboration with NetApp
AMHERST, N.Y., May 15, 2019 (GLOBE NEWSWIRE) -- ATTO Technology, Inc., announced that it has teamed with NetApp to deliver ATTO FibreBridge 7600N as a key component in the MetroCluster continuous data availability solution.
ATTO FibreBridge 7600N storage controller enables synchronous site-to-site replication up to 300km, by providing low latency 32Gb Fibre Channel connections to NetApp flash and disk systems while maintaining high resiliency. FibreBridge 7600N supports up to 1.2 million IOPS and 6,400 MB/s per controller.
“We’re proud that ATTO is able to collaborate with NetApp for a third generation FibreBridge solution. We are excited and appreciative for the opportunity to take our business relationship to the next level,” says Tim Klein, CEO of ATTO Technology, Inc.
NetApp MetroCluster enhances the built-in high availability and nondisruptive operations of NetApp systems with ONTAP® software, providing an additional layer of protection for the entire storage and host environment.
“High performance and scalability are key to success in today’s data-driven digital transformation,” said Jay Subramanian, vice president, ONTAP Product Management, NetApp. “The combination of NetApp storage systems and ATTO connectivity solutions meet the superior performance, reliability, efficiency and scale demanded by today’s enterprise applications.”
FibreBridge 7600N is one of ATTO XstreamCORE™ storage controller products, just one of ATTO’s broad portfolio of connectivity solutions widely tested and certified for compatibility with all operating systems and platforms.
ATTO has been a global leader of storage, network connectivity and infrastructure solutions for data-intensive computing environments for over 30 years. To browse the entire ATTO Technology family of connectivity solutions, visit: www.atto.com.
Purchase ATTO products through leading Value Added Resellers, System Integrators and the ATTO Web Store. Learn more: www.atto.com/howtobuy/
For over 30 years ATTO Technology, Inc. has been a global leader across the IT and media & entertainment markets, specializing in storage and network connectivity and infrastructure solutions for the most data-intensive computing environments. ATTO works with partners to deliver end-to-end solutions to better store, manage and deliver data. Working as an extension of customers’ design teams, ATTO manufactures host bus adapters, network adapters, storage controllers, Thunderbolt™ adapters, and software. ATTO solutions provide a high level of connectivity to all storage interfaces, including Fibre Channel, SAS, SATA, iSCSI, Ethernet, NVMe and Thunderbolt. ATTO is the Power Behind the Storage.
All trademarks, trade names, service marks and logos referenced herein belong to their respective companies.
Contact: Susannah Boutet
ATTO Technology, Inc.
Phone: +1 (716) 691-1999 x159
Fax: +1 (716) 691-9353
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
Biome Grow Inc. to Announce First Quarter Fiscal 2019 Financial Results.24.5.2019 19:08:00 CEST | Pressemelding
TORONTO, May 24, 2019 (GLOBE NEWSWIRE) -- Biome Grow Inc. (“Biome” or the “Company”) (CSE:BIO, OTCQB: BIOIF, 6OTA:GR) will release its financial results for the first quarter ended March 31, 2019 before market open on May 29, 2019. Following the release of its first quarter 2019 financial results, Biome will host a conference call and audio webcast with Khurram Malik, CEO at 8:30am Eastern Time May 29, 2019. Webcast information A live audio webcast will be available at https://event.on24.com/wcc/r/2015980/CEAD1B37BDD7710D021A38D2B79B5C45 Calling Information Toll Free Dial-In Number: 1 (866) 211 3199 International Dial-In Number (647) 689 6601 Conference ID 8693906 About Biome Biome wholly owns five subsidiaries, including: The Back Home Medical Cannabis Corporation, a company incorporated under the laws of the Province of Newfoundland and Labrador and in the late stages of applying for a license under the Cannabis Act; Great Lakes Cannabis, a company incorporated under the laws of the
Jason Lamb of Gates Foundation Named New Chair of CGAP’s Executive Committee24.5.2019 17:04:00 CEST | Pressemelding
CGAP CEO calls for renewed focus on retail credit to support growth and jobs for the poor Beirut, Lebanon, May 24, 2019 (GLOBE NEWSWIRE) -- Jason Lamb from the Bill & Melinda Gates Foundation, was elected chair of the Executive Committee for The Consultative Group to Assist the Poor (CGAP) at its annual meeting on Wednesday. Lamb will succeed Carolina Trivelli, senior researcher at the Instituto de Estudios Peruanos and Peru’s former Minister of Development and Social Inclusion. Under Trivelli’s leadership CGAP adopted its new five-year strategy and theory of change that places empowering the poor through financial services to capture opportunities and build resilience at the heart of CGAP’s work. At the Gates Foundation, Lamb is Deputy Director, Financial Services for the Poor (FSP) and manages focus country implementation in Bangladesh, Pakistan, Indonesia, Nigeria, Tanzania, Kenya and Uganda. He has served on CGAP’s Executive Committee, which functions like a board of directors prov
Gainsight Unveils the Customer Cloud, the Future of Customer Success Technology23.5.2019 19:30:00 CEST | Pressemelding
New Products Announced at Pulse 2019 to Drive Customer Success Across the Enterprise SAN FRANCISCO, May 23, 2019 (GLOBE NEWSWIRE) -- Today, Gainsight® launched the Customer Cloud —a first-of-its-kind solution for subscription businesses looking to adopt a customer-centric philosophy that enables them to retain customers while also driving company growth post-sale. According to the 2018 Subscription Economy Index report, subscription companies are growing five times faster than S&P and retail sales. The Gainsight Customer Cloud caters to these businesses by combining the company’s Customer Success and Product Experience products with three new product innovations to offer a powerful set of solutions for businesses to optimize their subscription strategies through technology. “With the maturity of cloud technology and the subscription economy, customer expectations have drastically changed. Companies are struggling to leverage existing tools to satisfy the increasing demands of their cus
Lowered Return Expectations Among Several Trends Pointing to a Shift in Private Markets Due Diligence says New eVestment Survey23.5.2019 15:30:00 CEST | Pressemelding
ATLANTA, May 23, 2019 (GLOBE NEWSWIRE) -- Private markets funds have continued to rake in new commitments from institutional investors eager to diversify their portfolios and capture the returns private markets investments can offer. However, investors are now tempering their private markets return expectations. Coupled with other industry trends, this will have implications for private markets fundraising and due diligence according to a new eVestment report, produced in association with parent company Nasdaq. The 2019 eVestment Private Markets Due Diligence Survey of institutional investors, consultants and private markets fund managers finds that 52% of investors expect returns in the space to decline in the future (page 16). Only 12% of investors expected private equity returns to increase, with the balance – 36% – expecting returns to stay about the same. Forty-seven percent of investors surveyed expect to see lower returns in venture capital vs. just 16% of investors who expect r
Collibra Announces 2019 Excellence Awards Winners23.5.2019 15:00:00 CEST | Pressemelding
American Express, Deloitte, and Lloyds Banking Group recognized as leaders in harnessing data to drive digital transformation NEW YORK, May 23, 2019 (GLOBE NEWSWIRE) -- Collibra, the leader in enterprise data governance and catalog software, today announced the winners of the 2019 Collibra Excellence Awards. Presented at the annual Data Citizens conference in New York, the awards honor teams and individuals driving innovative data strategy by collaborating with Collibra. “In today’s market, organizations that are able to maximize data have the power to transform entire industries,” said Felix Van de Maele, co-founder and CEO of Collibra. “We’re proud to honor the recipients of the Collibra Excellence Awards, a cutting-edge group at the forefront of data-driven innovation.” The 2019 Collibra Excellence Award Winners: American Express — Distinguished Data Program of the Year American Express was recognized for its data governance transformation, which began as a compliance initiative and
XBiotech Announces Plan to Launch Randomized Phase 2b Study of Bermekimab in Hidradenitis Suppurativa23.5.2019 14:20:00 CEST | Pressemelding
AUSTIN, Texas, May 23, 2019 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced plans to advance its dermatology program for its true human antibody bermekimab with the launch of a randomized, double-blind, placebo controlled, Phase 2b clinical study in patients with moderate to severe Hidradenitis Suppurativa (HS). This Phase 2b study will evaluate safety and efficacy of bermekimab at different subcutaneous doses compared with placebo. The study will further evaluate efficacy of bermekimab in HS and guide dosing strategies for the anticipated Phase 3 registration study. The Company expects the first patient to be enrolled during the third quarter of 2019. The Phase 2b study follows two previous successful clinical studies of bermekimab to treat HS. XBiotech recently evaluated bermekimab in a phase 2 study involving two groups of patients with HS: those who had no prior treatment with biologics; and those who had failed the only approved biological therapy to treat HS. The study, whi